Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Paroxetine in Colon Cancer: MET and ERBB3
2026-09-29
Jang et al. investigated whether the established SSRI paroxetine could be repositioned against colon cancer and linked its activity to MET/ERBB3-associated signaling. Across HCT116 and HT-29 cells and an HT-29 xenograft model, the study reported reduced viability, apoptosis, impaired colony and three-dimensional spheroid growth, and tumor suppression, while emphasizing preclinical rather than clinical evidence.
-
Cy3 TSA Fluorescence System Kit: Mechanism & Use
2026-09-29
The Cy3 TSA Fluorescence System Kit is a TSA fluorescence kit for HRP-assisted signal amplification in immunohistochemistry, immunocytochemistry, and in situ hybridization. Its localized Cy3 deposition supports fluorescence microscopy detection of low-abundance biomolecules while defined optical and storage parameters support reproducible workflow planning.
-
Faropenem Transport by Renal Npt1
2026-09-28
The reference study identified the inorganic phosphate transporter Npt1 as a chloride-sensitive, sodium-independent pathway for faropenem movement across the renal tubular luminal membrane. Its Xenopus oocyte experiments provide a mechanistic basis for understanding active renal secretion of this penem antibiotic while defining important limits for translation to intact kidney and clinical pharmacokinetic systems.
-
CS18 Targets TopBP1 to Counter Cancer Drug Resistance
2026-09-28
Lin and colleagues report CS18, a structurally distinct inhibitor of TopBP1-BRCT7/8 that disrupts oncogenic signaling while sparing DNA replication. In preclinical models, CS18 enhanced PARP inhibitor activity and improved osimertinib sensitivity, supporting further study of TopBP1 as a strategy for addressing treatment resistance.
-
CKI 7 Dihydrochloride: Practical Assay Guide
2026-09-27
A scenario-based guide to using CKI 7 dihydrochloride (SKU B4936) in cell viability, proliferation, and cytotoxicity workflows. It covers assay controls, handling, interpretation, and the limits of current evidence so researchers can plan informative CK1 experiments without overclaiming.
-
PSPro Spatial Proteomics at Single-Cell-Type Resolution
2026-09-26
Mao and colleagues introduce PSPro, an antibody-targeted proximity-labeling workflow that enriches cell-type-associated proteins directly from tissue slices for proteomic analysis. Its combination with laser microdissection supports comparisons of spatially distinct tumor and immune cell populations, complementing imaging-based approaches with broader protein identification.
-
HR-LCMS/MS Reveals a New Glabrol-Producing Astragalus
2026-09-25
Bolikhova and colleagues describe a bioactivity-guided HR-LCMS/MS workflow that connects autophagy responses in SH-SY5Y cells with chemical profiles of plant-extract fractions. Applying it to botanical extracts led them to identify Astragalus dasyanthus as a previously unreported source of the autophagy inducer glabrol, while highlighting the value—and limits—of pairing LC3-based screening with mass-spectrometric dereplication.
-
ω-Agatoxin IVA Reveals Low-Affinity N-Type Block
2026-09-25
Whole-cell recordings by Sidach and Mintz showed that micromolar v-agatoxin-IVA can incompletely inhibit neuronal N-type calcium current, in addition to its potent action on P-type channels. The study clarifies how toxin concentration and voltage-dependent effects shape pharmacological channel classification, and cautions against using high toxin concentrations to identify Q-type currents.
-
Stat3 Links Fyn to Dopaminergic Neurodegeneration
2026-09-24
A 2024 zebrafish study uses neural-specific expression of constitutively active Fyn to connect dopaminergic neuron loss and microglial activation with Stat3 and NF-κB signaling. Its live-imaging, transcriptomic and inhibitor experiments support a cooperative role for these pathways, while leaving the initiating neuron-to-microglia signals and relevance to mammalian disease for further study.
-
From Sterol Perturbation to Antiviral Translation
2026-09-24
DHCR7 connects cholesterol synthesis with immune phenotypes, but genetic evidence and chemical inhibition answer different questions. Explore how AY 9944 dihydrochloride can support controlled sterol studies—and how to interpret its results against new dhcr7 knockout evidence in grass carp.
-
JZL184 Workflows for MAGL and TBI Research
2026-09-24
Use JZL184 to raise endogenous 2-AG and probe MAGL–CB1 signaling alongside astrocyte GLT-1 and neuronal injury readouts. This workflow connects a TBI time course with practical controls, assay choices, and troubleshooting without treating a mechanistic probe as a therapy.
-
UK-5099 (PF-1005023): MPC Inhibitor Guide
2026-09-23
UK-5099, also called PF-1005023, is a mitochondrial pyruvate carrier inhibitor used to study pyruvate transport and cellular energy metabolism. Its reported effects include reduced pyruvate-dependent oxygen consumption, altered nucleotide energy balance, and glucose tolerance impairment in defined experimental models.
-
Metformin HCl: Reliable Assay Workflows
2026-09-22
A scenario-based guide to using Metformin Hydrochloride (Metformin HCl), SKU B1970, in viability, proliferation, cytotoxicity, and immunometabolic assays. It connects mechanism, formulation, protocol controls, and data interpretation to improve reproducibility without overstating what a metabolic readout proves.
-
SM-102 for mRNA Delivery: Evidence and Workflow
2026-09-22
SM-102 is an ionizable lipid component used in lipid nanoparticles for mRNA delivery and mRNA vaccine development. Product specifications support a molecular weight of 710.18 g/mol, 98.00% purity, ethanol solubility of at least 175.8 mg/mL, and storage at −20 °C or below, while current peer-reviewed evidence should not be interpreted as a direct SM-102 performance benchmark.
-
Metformin HCl: From AMPK Biology to Fibrosis Strategy
2026-09-21
A translational perspective on how Metformin Hydrochloride connects metabolic control with AMPK-centered antifibrotic research, using vocal fold fibrosis as a model for mechanism-led experimental design.